MedTrace Logo

Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer

NCT01394211 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2018-07-26

Study results available
· View outcomes & findings →

Summary

This phase II trial studies how well giving pazopanib hydrochloride and anastrozole before surgery works in treating patients with stage II-III estrogen receptor-positive breast cancer. Pazopanib hydrochloride and anastrozole may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pazopanib hydrochloride and anastrozole together before surgery may make the tumor smaller and reduce the amount of normal cells that have to be removed

Conditions

  • Estrogen Receptor-positive Breast Cancer
  • Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
  • Male Breast Cancer
  • Recurrent Breast Cancer
  • Stage II Breast Cancer
  • Stage IIIA Breast Cancer
  • Stage IIIB Breast Cancer

Interventions

DRUG

anastrozole

Given PO

DRUG

pazopanib hydrochloride

Given PO

PROCEDURE

therapeutic conventional surgery

Undergo definitive surgery

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • GlaxoSmithKline

    collaborator INDUSTRY

  • University of Arizona

    lead OTHER

Principal Investigators

  • Robert Livingston · University of Arizona

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-13
Primary Completion
2012-04-12
Completion
2012-04-12

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01394211 on ClinicalTrials.gov